Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been given a consensus recommendation of "Buy" by the nine ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $213.75.

A number of equities research analysts have recently weighed in on KRYS shares. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. Citigroup reissued a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. Guggenheim lowered their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. Corporate insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KRYS. Swiss National Bank lifted its holdings in shares of Krystal Biotech by 8.4% during the 4th quarter. Swiss National Bank now owns 42,400 shares of the company's stock valued at $6,642,000 after buying an additional 3,300 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Krystal Biotech by 4.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock valued at $762,000 after buying an additional 190 shares during the period. Cibc World Markets Corp bought a new position in shares of Krystal Biotech during the 4th quarter valued at $364,000. Xponance Inc. raised its holdings in Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company's stock worth $280,000 after purchasing an additional 155 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Krystal Biotech by 27.3% in the 4th quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after purchasing an additional 1,369 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Krystal Biotech stock traded down $2.66 during midday trading on Friday, hitting $147.49. 303,976 shares of the company's stock were exchanged, compared to its average volume of 287,107. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $219.34. The stock has a 50-day moving average price of $136.57 and a two-hundred day moving average price of $155.93. The company has a market cap of $4.26 billion, a P/E ratio of 35.45 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. As a group, sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).